查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1159170

家族性腺瘤息肉症治疗的全球市场(2022年～2028年)

Familial Adenomatous Polyposis Treatment Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

全球家族性腺瘤息肉症治疗的市场规模在预测期间内预计将以13.9％的年复合成长率增长。在全世界家族性腺瘤息肉症的盛行率持续增加，促进了市场的成长。

本报告提供全球家族性腺瘤息肉症治疗市场相关调查分析，提供市场概要，竞争情形，市场分析，企业简介等系统性资讯。

目录

第1章 报告概要

第2章 市场概要与洞察

  • 调查范围
  • 分析师的洞察和目前市场趋势

第3章 竞争情形

  • 主要企业分析
    • Cancer Prevention Pharmaceuticals
    • Marina Biotech
    • Thetis Pharmaceuticals LLC
    • Emtora Biosciences
    • Cancer Prevention Pharmaceuticals
  • 主要策略分析
  • COVID-19对主要企业带来的影响

第4章 市场区隔

  • 全球家族性腺瘤息肉症治疗市场:各类型
    • ikosapento
    • efurorunichin盐酸盐
    • 阿斯匹林
    • CEQ-508
    • 其他
  • 全球家族性腺瘤息肉症治疗市场:各用途
    • 医院
    • 诊所
    • 其他

第5章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 全球其他地区

第6章 企业简介

  • Cancer Prevention Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Thetis Pharmaceuticals LLC
  • SLA Pharma
Product Code: OMR2025847

Global Familial Adenomatous Polyposis Treatment Market Size, Share, and Trends Analysis Report, By Type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, and Others), By Application (Clinic, Hospital, and Others) for the Forecast (2022-2028)

The global familial adenomatous polyposis treatment market is anticipated to grow at a significant CAGR of 13.9 % during the forecast period. FAP is a condition that is passed on down the generations. It is characterized by cancers of the large intestine (colon) and the rectum. Furthermore, in adults, the common form of familial adenomatous polyposis develops in adolescence, leading the colon to generate a large number of noncancerous polyps. One of the main factors driving the market's growth is the increasing prevalence of familial adenomatous polyposis throughout the world.

The global adenomatous polyposis treatment market is segmented based on type and application. Based on the type, the market is segmented into Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, and others. Based on the application, the market is sub-segmented into the Hospital, Clinics, and others. The Icosapent is expected to drive the growth of the market due to Icosapent reduces rectal polyp number and size in familial adenomatous polyposis.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among all segments, the North America region is expected to propel the growth of the market over the forecast. Due to the availability of developed healthcare infrastructure across the region is expected to fuel the market growth.

The major companies serving the global adenomatous polyposis treatment market include Cancer Prevention Pharmaceuticals, Marina Biotech, and Thetis Pharmaceuticals LLC are a few of the market's main companies. To remain competitive in the market, industry players are using different tactics such as mergers and acquisitions, regional expansion, partnerships and collaborations, and new product launches, which contribute considerably to market growth. For instance, in September 2021, Recursion a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning, and engineering, announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis (FAP). REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small-molecule inhibitor of MEK1 and MEK2 being developed to reduce tumor size in FAP patients.

Research Methodology

The market study of the global familial adenomatous polyposis treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Familial Adenomatous Polyposis Treatment Market Research and Analysis by Type.

2. Global Familial Adenomatous Polyposis Treatment Market Research and Analysis by Application.

The Report Covers:

  • Comprehensive Research Methodology of the global familial adenomatous polyposis treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global familial adenomatous polyposis treatment market.
  • Insights about market determinants that are stimulating the global familial adenomatous polyposis treatment market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Familial Adenomatous Polyposis Treatment Market
  • Recovery Scenario of Global Familial Adenomatous Polyposis Treatment Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Cancer Prevention Pharmaceuticals
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Marina Biotech
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Thetis Pharmaceuticals LLC
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. Emtora Biosciences
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Cancer Prevention Pharmaceuticals
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Familial Adenomatous Polyposis Treatment Market by Type
    • 4.1.1. Icosapent
    • 4.1.2. Eflornithine hydrochloride
    • 4.1.3. Aspirin
    • 4.1.4. CEQ-508
    • 4.1.5. Others
  • 4.2. Global Familial Adenomatous Polyposis Treatment Market by Application
    • 4.2.1. Hospitals
    • 4.2.2. Clinics
    • 4.2.3. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Cancer Prevention Pharmaceuticals, Inc.
  • 6.2. Marina Biotech, Inc.
  • 6.3. Thetis Pharmaceuticals LLC
  • 6.4. SLA Pharma

LIST OF TABLES

  • 1. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL ICOSAPENT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL EFLORNITHINE HYDROCHLORIDE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ASPIRIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CEQ-508 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL OTHER FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 8. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 15. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET, 2022-2028 (%)
  • 4. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL ICOSAPENT FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL EFLORNITHINE HYDROCHLORIDE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL APSIRIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CEQ-508 FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL OTHER FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 11. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT FOR OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD FAMILIAL ADENOMATOUS POLYPOSIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)